MAZE - NASDAQ

Maze Therapeutics, Inc.

MAZE·NASDAQ

$25.40

+4.6%

HealthcareBiotechnology

Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States. Its lead programs includes MZE829, an oral small molecule inhibitor of apolipoprotein L1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor of the solute transporter SLC6A19, which is in phase I clinical trial for the treatment of chronic kidney disease. Maze Therapeutics, Inc. was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$1.41B

EPS-3.0500

P/E Ratio-8.33

Earnings Date08/11/2026

maze

Total Investments

Last Annual Value

171.87M

3-Year CAGR

422%

5-Year CAGR

169%

10-Year CAGR

64%

Adjust for Inflation

Maze Therapeutics, Inc. Competitors Analysis of Total Investments

MAZE · NASDAQ

Company	Total Investments	CAGR 3Y	CAGR 5Y	CAGR 10Y
Maze Therapeutics, Inc. NASDAQ:MAZE	171.87M	440.6%	N/A	N/A
Immunome, Inc. NASDAQ:IMNM	210.00K	-82.6%	16.0%	N/A
Ardelyx, Inc. NASDAQ:ARDX	196.69M	6.5%	34.8%	4.5%
Trevi Therapeutics, Inc. NASDAQ:TRVI	169.35M	49.6%	N/A	N/A
Spyre Therapeutics, Inc. NASDAQ:SYRE	670.81M	64.6%	53.8%	45.5%
Intellia Therapeutics, Inc. NASDAQ:NTLA	329.96M	-26.8%	-20.7%	N/A
BioCryst Pharmaceuticals, Inc. NASDAQ:BCRX	246.18M	-4.0%	89.6%	19.5%
Sionna Therapeutics, Inc. NASDAQ:SION	177.43M	N/A	N/A	N/A

Maze Therapeutics, Inc. Fair Value Envelope

MAZE · NASDAQ

Our analysis suggests that MAZE has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $25.4, this represents a potential HIDDEN relative to our calculated worth for Maze Therapeutics, Inc..

HIDDEN

Intrinsic Value

Current Price: $25.4

Related Guides

Blog Categories

Continue your MAZE research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.